Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

    NCT07303699 · start 2026-01-03

    Registered record
    Registry ID
    NCT07303699
    Conditions
    Pulmonary Tuberculosis (TB)
    Interventions
    Atorvastatin 20 mg; Atorvastatin 40 mg; Atorvastatin 60 mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamid (Z) Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-03
    Completion
    2028-03-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis (TB)
    InterventionAtorvastatin 20 mg; Atorvastatin 40 mg; Atorvastatin 60 mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamid (Z) Ethambutol (E)
    PhasePhase 2
    Registry statusRecruiting

  • Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort

    NCT07268664 · start 2025-12-01

    Registered record
    Registry ID
    NCT07268664
    Conditions
    Rifampicin Resistant Tuberculosis; Pulmonary Tuberculosis; Tuberculosis; Drug-resistant Tuberculosis
    Interventions
    BLMZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2028-08-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin Resistant Tuberculosis; Pulmonary Tuberculosis; Tuberculosis; Drug-resistant Tuberculosis
    InterventionBLMZ
    PhasePhase 3
    Registry statusNot yet recruiting

  • Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

    NCT07163143 · start 2025-11

    Registered record
    Registry ID
    NCT07163143
    Conditions
    Tuberculosis (TB)
    Interventions
    Isoniazid (H); Rifampicin (R); Pyrazinamide (Z); Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-11
    Completion
    2029-04
    Enrolment
    784

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis (TB)
    InterventionIsoniazid (H); Rifampicin (R); Pyrazinamide (Z); Ethambutol (E)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

    NCT07086820 · start 2025-10-27

    Registered record
    Registry ID
    NCT07086820
    Conditions
    Tuberculosis Infection; Household Contacts; Children; Adolescent; Tuberculosis Infection, Latent; Tuberculosis
    Interventions
    Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-27
    Completion
    2028-11
    Enrolment
    647

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection; Household Contacts; Children; Adolescent +2 more
    InterventionTuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks; Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

    NCT07209761 · start 2025-10-16

    Registered record
    Registry ID
    NCT07209761
    Conditions
    Pulmonary Tuberculosis
    Interventions
    BPaQM; BPaLM; BPaQ; BPaL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2028-09-29
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBPaQM; BPaLM; BPaQ; BPaL
    PhasePhase 3
    Registry statusRecruiting

  • Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

    NCT06441006 · start 2025-10-03

    Registered record
    Registry ID
    NCT06441006
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
    Interventions
    Bedaquiline; Linezolid; Pretomanid; Moxifloxacin; Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-10-03
    Completion
    2031-08
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
    InterventionBedaquiline; Linezolid; Pretomanid; Moxifloxacin +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis

    NCT07191834 · start 2025-09-30

    Registered record
    Registry ID
    NCT07191834
    Conditions
    Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis; Type 2 Diabetes Mellitus (T2DM); Pretomanid
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2027-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis; Type 2 Diabetes Mellitus (T2DM); Pretomanid
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

    NCT07170800 · start 2025-09-19

    Registered record
    Registry ID
    NCT07170800
    Conditions
    Tuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    Interventions
    JDB0131 100mg; JDB0131 200mg; Delamanid (D)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-19
    Completion
    2026-09-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Pulmonary Tuberculosis; Rifampicin-resistant Tuberculosis
    InterventionJDB0131 100mg; JDB0131 200mg; Delamanid (D)
    PhasePhase 2
    Registry statusRecruiting

  • Ultra-Short Regimen for Elderly DS-TB

    NCT07076225 · start 2025-07-25

    Registered record
    Registry ID
    NCT07076225
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-07-25
    Completion
    2030-07-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +3 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • A PAN-USR TB Multi-Center Trial

    NCT06905522 · start 2025-06-18

    Registered record
    Registry ID
    NCT06905522
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E); Moxifloxacin (M); Pretomanid (Pa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-18
    Completion
    2029-12
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +5 more
    PhasePhase 3
    Registry statusRecruiting

  • Shorter and Safer Treatment Regimens for Latent TB

    NCT06498414 · start 2025-06-10

    Registered record
    Registry ID
    NCT06498414
    Conditions
    Tuberculosis Infection, Latent
    Interventions
    rifampin standard arm; rifampin double dose; levofloxacin and rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-06-10
    Completion
    2029-06-01
    Enrolment
    1,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Infection, Latent
    Interventionrifampin standard arm; rifampin double dose; levofloxacin and rifapentine
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

    NCT06917495 · start 2025-04-05

    Registered record
    Registry ID
    NCT06917495
    Conditions
    Mild Spinal Tuberculosis
    Interventions
    Rifampin; Isoniazid; Rifapentine (RPT); Moxifloxacin; Pyrazinamide; Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-04-05
    Completion
    2029-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Spinal Tuberculosis
    InterventionRifampin; Isoniazid; Rifapentine (RPT); Moxifloxacin +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

    NCT06192160 · start 2025-03-11

    Registered record
    Registry ID
    NCT06192160
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Bedaquiline; Pretomanid; Linezolid; TBI-223; Sutezolid; TBI-223; Sutezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-11
    Completion
    2027-08-11
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +7 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

    NCT06748937 · start 2025-03-03

    Registered record
    Registry ID
    NCT06748937
    Conditions
    Tuberculosis
    Interventions
    Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-03
    Completion
    2026-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAlpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    PhasePhase 2
    Registry statusRecruiting

  • Shortened Regimen for Drug-susceptible TB in Children

    NCT06253715 · start 2025-01-15

    Registered record
    Registry ID
    NCT06253715
    Conditions
    Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2027-09-30
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 3
    Registry statusRecruiting